TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02354872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5Rs Motivation Counseling
Description: The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5Rs Motivation Counseling
Description: The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
Study: NCT04080739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivicaine 0.2%
Description: 2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.
Study: NCT03530839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrodesis
Description: see study group description

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection arthroplasty
Description: see study group description
Study: NCT01004809

Intervention type: DRUG
Intervention: Dutasteride
Description: Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT03904290

Intervention type: OTHER
Group type: OTHER
Intervention: PFO Closure
Description: Subject will undergo percutaneous closure of PFO/ASD utilizing FDA-approved PFO/ASD closure device(s).
Study: NCT01907230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: In the prophylactic group, participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment (adjust dosage according to renal function) will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
Study: NCT00871208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Altabax (R)
Description: Retapamulin 1% ointment is to be applied to lesional atopic dermatitis twice-daily in addition to a topical corticosteroid (Locoid lipocream (R))

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle and Locoid lipocream (R)
Description: The vehicle base of retapamulin ointment will be applied twice-daily to active lesions of atopic dermatitis in addition to locoid lipocream (R)
Study: NCT02333903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Physical Activity
Description: 1.5 hours physical training sessions, twice a week for 1 year, under the supervision of a dedicated coach specialized in supporting overweighted patients.~Typical training session organized for small groups (5 patients) will consist of aerobic exercises, muscular strengthening (4 peripheral members and abdominal muscular belt), followed by stretching exercises.
Study: NCT00754078

Intervention type: RADIATION
Group type: OTHER
Intervention: Tomotherapy
Description: 30 fractions of tomotherapy treatment
Study: NCT00445432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)
Study: NCT00956423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate-intensity aerobic and resistance training
Description: Individuals will complete four days of aerobic exercise of moderate intensity (60% of maximal VO2, approximated from heart rate). Duration of aerobic activity will gradually increase from weeks 1 through 4 until 180 min of aerobic exercise at the prescribed intensity is performed each week. Following aerobic exercise on two days per week, moderate-intensity resistance training will be performed using eight different resistance machines. One set of 8-12 repetitions will be performed during weeks 1-4; from week 5-on, 2 sets of 8-12 repetitions will be performed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low-intensity stretching
Description: Individuals will perform supervised whole-body flexibility exercises on two days per week. Two sets of each exercise will be performed, with the duration of each stretch gradually increasing from 15 sec to 30 sec. A total of 15-20 stretches, focusing on whole-body flexibility, will be performed.
Study: NCT02721342

Intervention type: DRUG
Intervention: Ramipril, Irbesartan and Atorvastin
Study: NCT04680572

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroplasty
Description: arthroplasty for fracture neck of femur

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroplasty
Description: arthroplasty for fracture neck of femur
Study: NCT03850873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616
Description: TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily
Study: NCT03098212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: On the day of admission for labor. Pregnant women select type of essential oil. Aroma diffuser is used during labor. Pain score was record during latent, early active and late active phase.
Study: NCT00694200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine per os 50 mg 3 times a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg IV every 14 days
Study: NCT01981902

Intervention type: DEVICE
Intervention: Non-Invasive Optical Spectroscopic
Description: Non-Invasive Optical Spectroscopic
Study: NCT01452516

Intervention type: DEVICE
Group type: OTHER
Intervention: nanOss Bioactive Bone void filler
Description: Instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler

Intervention type: DEVICE
Group type: OTHER
Intervention: Interbody FCage
Description: Lumbar fusion using interbody cages with autograft. This will be done in conjunction with the posterolatreal gutter fusion
Study: NCT00029003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02054052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
Study: NCT01564043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: website and pedometer
Description: use of pedometer and website
Study: NCT01057680

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine monohydrate
Description: Powder, 0.1 g per day, 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sugar placebo
Description: powder, 0.1 g/day, 12 months
Study: NCT03759392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil
Description: Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo twice daily for up to 20 weeks
Study: NCT03101605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-learning teaching module
Description: As described

Intervention type: OTHER
Group type: OTHER
Intervention: Standard teaching method
Description: As described
Study: NCT03746847

Intervention type: DRUG
Intervention: Gallium-68 DOTATATE
Description: Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
Study: NCT05483790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the multimodal intervention
Description: The in-person training course included 25 minutescognitive training activities were conducted for , followed by a 15-minute healthy lifestyle education. After a 10-minute break, physical exercise training was administered for 15 minutes. Finally, 15 minutes wrap-up session.~The cognitive training encompassed memory-related training and attention-related training. The physical exercise included finger exercises, elastic band exercises, Tai Chi/ Baduanjin with guidance. The healthy lifestyle education included guidance on nutrition, sleep, stress management, and mood adjustment by teaching problem-solving skills. Additionally, the intervention provided information and support to facilitate lifestyle changes and included discussions and practical exercises, such as tools for assessing dietary behavior.
Study: NCT02593617

Intervention type: OTHER
Group type: OTHER
Intervention: Addiction Profile Index

Intervention type: OTHER
Group type: OTHER
Intervention: Addiction Profile Index

Intervention type: OTHER
Group type: OTHER
Intervention: Addiction Profile Index

Intervention type: OTHER
Group type: OTHER
Intervention: Addiction Profile Index

Intervention type: OTHER
Group type: OTHER
Intervention: Addiction Profile Index

Intervention type: OTHER
Group type: OTHER
Intervention: Addiction Profile Index

Intervention type: OTHER
Group type: OTHER
Intervention: Alcohol Use Disorders Identification Test

Intervention type: OTHER
Group type: OTHER
Intervention: Alcohol Use Disorders Identification Test

Intervention type: OTHER
Group type: OTHER
Intervention: Alcohol Use Disorders Identification Test

Intervention type: OTHER
Group type: OTHER
Intervention: Alcohol Use Disorders Identification Test

Intervention type: OTHER
Group type: OTHER
Intervention: Alcohol Use Disorders Identification Test

Intervention type: OTHER
Group type: OTHER
Intervention: Alcohol Use Disorders Identification Test

Intervention type: OTHER
Group type: OTHER
Intervention: Barratt Impulsiveness Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Barratt Impulsiveness Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Barratt Impulsiveness Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Barratt Impulsiveness Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Barratt Impulsiveness Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Barratt Impulsiveness Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Zuckerman Sensation Seeking Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Zuckerman Sensation Seeking Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Zuckerman Sensation Seeking Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Zuckerman Sensation Seeking Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Zuckerman Sensation Seeking Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Zuckerman Sensation Seeking Scale

Intervention type: OTHER
Group type: OTHER
Intervention: Energy Drink Consumption Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Energy Drink Consumption Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Energy Drink Consumption Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Energy Drink Consumption Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Energy Drink Consumption Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Energy Drink Consumption Questionnaire
Study: NCT00419497

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paleolithic diet vs Mediterranean diet
Description: Prudent diets with or without grains and dairy
Study: NCT02399137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03450382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hans Kai Education
Description: 9 weeks of health education classes preceding social group formation into Hans Kai. Peer led support focused on behavioural change.
Study: NCT05532202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NICU Mom and Baby Net
Description: See arm descriptions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NICU Developmental Awareness System
Description: See arm description.
Study: NCT01577758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0264
Description: MLN0264 30-minute infusion on Day 1 of each treatment cycle
Study: NCT02608463

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Visual Analogue Scale
Description: 100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.
Study: NCT02459977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Basiliximab induction therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No basiliximab
Description: No basiliximab induction therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplantation
Description: kidney transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Description: kidney transplantation
Study: NCT01865162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
Study: NCT01071928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404
Description: ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
Study: NCT00984854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
Study: NCT02608463

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Visual Analogue Scale
Description: 100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Visual Analogue Scale
Description: 100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.
Study: NCT00984854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
Study: NCT02608463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale
Description: 100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale
Description: The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale
Description: The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale
Description: The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale
Description: The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
Study: NCT03386487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF 04457845
Description: Study medication will be administered at 4mg by mouth daily for eight weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo comparator will be administered by mouth daily for eight weeks.
Study: NCT00984854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered just prior to wounding and 200μl administered 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 600mM (16.93mg/100μl) administered just prior to wounding and 200μl administered 24 h later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
Study: NCT00122174

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress Busting Program for family caregivers
Study: NCT03071822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: PIGLETs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: PIGLETs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: PIGLETs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: PIGLETs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: PIGLETs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: PIGLETs
Study: NCT02630914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The AtriCure Synergy Ablation System
Description: The AtriCure Synergy Ablation System will be used on all patients for AF ablation.
Study: NCT00248586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard CBT (S-CBT)
Description: Standard CBT (S-CBT) is a skills-based training program delivered to patients in 10 weekly, 1-hour sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal contact CBT (MC-CBT)
Description: Minimal contact CBT (MC-CBT) covers the same range of procedures featured in S-CBT but relies extensively on self study materials.
Study: NCT02764658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary recovery on the AECOPD
Description: The combination effect of negative pressure ventilation, limb muscle exercise training program and fibit monitor on acute exacerbation of AECOPD. To investigate the daily physical activity in routine care patients with after AECOPD and stable stage.
Study: NCT02125799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated HF-rTMS (Magstim Rapid 2 stimulator)
Description: Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
Study: NCT02764658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care on the AECOPD
Description: To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Routine care patients wtih AECOPD and stable stage.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine care on the AECOPD
Description: To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Routine care patients wtih AECOPD and stable stage.